
Initiator Pharma obtains IP2018 patent in Europe for treatment of Erectile Dysfunction and Depression

Initiator Pharma A/S, a clinical-stage pharma company developing innovative drugs targeting key unmet medical needs within the central and peripheral nervous system, announced today that the European Patent Office (“EPO”) has granted the company’s patent application for the product candidate IP2018, targeting monoamine reuptake transporters.

The patent granted by the EPO as EP 4009942 B1 concerns the company’s product candidate IP2018 for treatment of Erectile Dysfunction (ED) and Depression. The granted patent confers protection in Europe until 2040. Corresponding patents have previously been granted in Israel and South Africa, and applications are pending in a large number of additional territories such as, the US, Japan and China.

“We are excited to receive grant of this medical use patent, which extends the protection for IP2018 and strengthens the exclusivity for our drug pipeline. We expect that the important grant in Europe will play an essential role in the future commercialization strategy for IP2018,” says Claus Elsborg Olesen, CEO at Initiator Pharma. “

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of two clinical stage assets – pudafensine (IP2015) and IP2018 – and two preclinical assets. The company is currently conducting a Phase IIb trial with pudafensine (IP2015) in erectile dysfunction of organic origin, and successfully completed a Phase I proof of principle trial in neuropathic pain in 2022. With IP2018 the company is conducting a Phase IIa trial for the treatment of erectile dysfunction of psychogenic origin.

Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments

[Initiator Pharma obtains IP2018 patent in Europe for treatment of Erectile Dysfunction and Depression](#)